Business Overview: Aquestive Therapeutics, Inc. (Nasdaq: AQST)

---

Executive Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company built around its proprietary PharmFilm oral thin-film drug delivery technology, which enables drugs to be administered as a fast-dissolving film placed under the tongue or on the inner cheek rather than swallowed as a traditional pill or injected. This technology is particularly valuable for medications needed in emergency or acute situations where rapid, needle-free administration is critical, or for patients who have difficulty swallowing traditional tablets.

Aquestive's lead commercial product, Libervant (diazepam) buccal film, treats seizure clusters in epilepsy patients, providing a non-injectable rescue therapy alternative. The company also has a legacy licensing/royalty relationship tied to Sympazan (clobazam) oral film and has historically manufactured PharmFilm-based products for pharmaceutical partners.

---

1. Core Business Model & How They Work

Aquestive operates a hybrid specialty pharma model combining direct commercial products with drug delivery technology licensing/manufacturing partnerships:

[ PharmFilm Drug Delivery Platform ] ➡️ [ Develop/Reformulate Drugs as Oral Thin Films ] ➡️ [ Direct Commercialization (Libervant) OR Partner Licensing/Manufacturing ] ➡️ [ Revenue from Product Sales + Partner Royalties/Manufacturing Fees ]

Key Operational Drivers

1. Needle-Free Rescue Therapy Positioning: Libervant's key differentiation is providing a non-injectable, easy-to-administer rescue treatment for seizure clusters, an important improvement in convenience and reduced caregiver burden versus older rectal diazepam gel formulations.
2. Platform Technology Licensing/Manufacturing: Beyond its own commercial products, Aquestive's PharmFilm technology has been licensed and manufactured for pharmaceutical partners' branded products, providing a manufacturing/royalty revenue stream layered on top of direct product sales.
3. Epilepsy/Neurology Specialist Sales Focus: Commercial efforts for Libervant are targeted at neurologists and epileptologists who treat seizure disorder patients, a relatively concentrated specialist prescriber base.
4. Capital Structure Considerations: As a smaller specialty pharma company, Aquestive must balance continued commercial investment in Libervant against its capital position and any restructuring of legacy debt or royalty obligations.

---

2. Product Portfolio

---

3. Competitive Landscape

Competitors by Domain

Seizure Cluster Rescue Therapy

• Key Competitors: UCB's Nayzilam (midazolam nasal spray) and Neurelis's Valtoco (diazepam nasal spray) are the primary approved competing rescue therapies for seizure clusters, alongside older rectal diazepam gel (Diastat) formulations.
• Dynamics: The seizure rescue therapy market has shifted meaningfully toward non-rectal administration routes (nasal sprays and buccal films) over the past decade, with Libervant competing directly against Valtoco and Nayzilam on ease of use, onset of action, and prescriber/caregiver familiarity; being a later entrant in a market with established nasal spray competitors is a meaningful commercial challenge.

Oral Thin-Film Drug Delivery Technology

• Key Competitors: Indivior (historically a major user of oral film technology for Suboxone) and other drug delivery technology companies compete for pharmaceutical partner licensing and manufacturing relationships in the broader oral film and alternative drug delivery technology space.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Proprietary drug delivery platform: PharmFilm technology and associated manufacturing know-how represent a real, patent-protected technical capability applicable across multiple drug products.
• Needle-free convenience differentiation: Libervant's buccal film administration avoids both needles and the social/practical challenges of rectal gel administration, a meaningful caregiver and patient experience advantage.
• Dual revenue model optionality: The ability to both commercialize products directly and license/manufacture for partners provides some revenue diversification beyond a single commercial product's success.

Strategic Risks & Vulnerabilities

1. Late-Entrant Competitive Position: Valtoco and Nayzilam were approved and commercially established in the seizure rescue market ahead of Libervant, creating an uphill commercial battle for prescriber switching and market share capture.
   • Mitigation Strategy: Differentiated positioning around buccal (versus nasal) administration route preferences for specific patient populations and continued physician education efforts.
2. Commercial Execution and Capital Constraints: As a smaller specialty pharma company, Aquestive must carefully manage commercial investment spend against its capital position while building Libervant's market share.
3. Reimbursement and Formulary Access: Securing favorable payer formulary placement against established competitors is critical to commercial success and can be a slow, resource-intensive process.
4. Platform Licensing Dependency: Manufacturing/royalty revenue from partnered products depends on those partners' own commercial success and continued relationship terms, which are outside Aquestive's direct control.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Aquestive Therapeutics has built a differentiated needle-free rescue therapy for seizure clusters using its proprietary PharmFilm oral thin-film technology, entering a seizure rescue therapy market that has already shifted meaningfully away from rectal gel formulations toward nasal spray and buccal film alternatives.

The company's long-term commercial success depends on Libervant's ability to capture meaningful market share against already-established nasal spray competitors Valtoco and Nayzilam, while continuing to leverage its underlying PharmFilm platform technology for potential additional licensing and manufacturing partnership opportunities beyond its core epilepsy franchise.